Clinect has advised that Iopidine® Eye Drops will be removed from the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023, as follows:

Iopidine® Eye Drops
Apraclonidine 5mg/mL
ARTG 51190

Iopidine® Eye Drops will remain available to patients as a private product.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Clinect at [email protected] or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates